Assoc. Prof. Dr. Ferit Aslan

Formation et spécialisation

Dicle Üniversitesi Tıp Fakültesi — Formation médicale

İzmir Kâtip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi — Spécialisation en médecine interne

Ankara Dr. Abdurrahman Yurtaslan Onkoloji Eğitim ve Araştırma Hastanesi — Surspécialisation en oncologie médicale

Domaines d’expertise

Cancer du sein

Cancer du poumon

Cancer de la prostate

Cancers gastro-intestinaux

Cancers urogénitaux

Cancers gynécologiques

Immunothérapie

Expérience professionnelle

Medical Park Ankara Batıkent — Pratique clinique

Affiliations professionnelles

Association des maladies du sein d’Ankara

Société turque d’oncologie médicale

Société européenne d’oncologie médicale (ESMO)

Association médicale turque

Publications sélectionnées

Atabey P, Aslan F, Kılıç C, Yıldırım Ö, Özlügedik S. Level II (IIA/IIB) Lymph Node Evaluation in Head and Neck Cancer: A Retrospective Cohort Study from a Non-Endemic Region. J Clin Med. 2026;15(3):1068. doi:10.3390/jcm15031068. PMID:41682748.

Aslan F, Erkılıç B, Türkmen G, Günaydın E, Hasanov C. Renal Cell Carcinoma in Pregnancy With Breast Metastasis: A Case Report and Literature Review. Cureus. 2025;17(9):e92550. doi:10.7759/cureus.92550. PMID:41111781.

Yalçıntaş Arslan Ü, Aslan F, et al. Real-World Experience with Non-Metastatic Male Breast Cancer: A 222-Patient Multicenter Study from the Turkish Oncology Group (TOG). Cancers. 2025;17(24):3895. PMID:41463146.

Yıldız F, et al.. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study. 2026;62(4):763. PMID:42075632.

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. 2024. PMID:38310597.

Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment. 2024. PMID:38724585.

Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study. 2024. PMID:39616250.

Alyanak A, Aslan F. Gallbladder Polyp and Cancer Evaluation After Cholecystectomy: A Retrospective Observational Study. PMID:36127982.

Alyanak A, Aslan F, Alagözlü H. İntestinal metaplazili hastalarda sızdıran bağırsak sendromu tespitinde fekal zonulin biomarker olarak kullanılabilir mi?: prospektif kesitsel çalışma. Turkish Journal of Clinics and Laboratory. 2022. doi:10.18663/tjcl.1160928.

Aslan F, Erdur E, Yıldız F. Erişkinde nadir bir tümör olarak rabdomiyosarkom: Vaka serisi. Journal of Surgery and Medicine. 2020. doi:10.28982/josam.767956.

Aslan F, Demirci U, Kızılgöz D, Yıldız F, Kabalak PA, Başal FB, Eraslan E, Yılmaz Ü, Öksüzoğlu B. İleri evre küçük hücre dışı akciğer kanserinde üçüncü basamak tedavide sağ kalımı ekileyen prognostik faktörler: Retrospektif kohort çalışma. Journal of Surgery and Medicine. 2020. doi:10.28982/josam.686819.

Chapitres d’ouvrages

Aslan F, Budakoğlu B. Erişkin rabdomiyosarkomlarında tedavi yaklaşımı. Yalçıntaş Arslan Ü, editör. Yumuşak Doku Sarkomlarının Tedavisinde Güncel Yaklaşımlar. Ankara: Türkiye Klinikleri; 2023. p.79–84.